Division of Oncology, Department of Internal Medicine, Medical University of Graz (MUG), Graz, Austria.
J Urol. 2012 Mar;187(3):834-9. doi: 10.1016/j.juro.2011.10.155. Epub 2012 Jan 15.
We assessed whether supplementing the Leibovich prognosis score with vascular invasion would improve prognostic value to predict metastatic disease in patients with nonmetastatic clear cell renal cell carcinoma.
We retrospectively evaluated the pathology records of 1,754 patients with nonmetastatic clear cell renal cell carcinoma treated with surgery between 1984 and 2006 at a single tertiary academic center. The Leibovich prognosis score was supplemented by additional scoring for vascular invasion. Metastasis-free survival was assessed using the Kaplan-Meier method for each score category. A Cox regression model was used for multivariate testing. Predictive accuracy was determined by the Harrell concordance index and decision curve analysis.
Median followup was 84 months. Ten-year metastasis-free survival probability for a score of 0 to 1 and 2 to 8 or greater was 95%, 83%, 78%, 81%, 69%, 51%, 15% and 13%, respectively. The concordance index was 0.792 compared to 0.778 from our external validation of the Leibovich prognosis score using routine pathological findings (p <0.05). Decision curve analysis also favored the predictive ability of the novel model.
Adding vascular invasion improved the predictive accuracy of our validation data by 1.4% over that of the Leibovich prognosis score. Patients with a score of 7 or greater had a more than 85% probability of metastatic disease at 10 years. Thus, they could be considered candidates for adjuvant treatment trials.
我们评估了 Leibovich 预后评分中加入血管侵犯是否能提高预测非转移性透明细胞肾细胞癌患者发生转移疾病的预后价值。
我们回顾性评估了 1984 年至 2006 年间在单一三级学术中心接受手术治疗的 1754 例非转移性透明细胞肾细胞癌患者的病理记录。Leibovich 预后评分通过血管侵犯的额外评分进行补充。使用 Kaplan-Meier 方法评估每个评分类别的无转移生存情况。Cox 回归模型用于多变量检验。预测准确性通过 Harrell 一致性指数和决策曲线分析确定。
中位随访时间为 84 个月。评分 0-1 和 2-8 或更高的患者 10 年无转移生存率分别为 95%、83%、78%、81%、69%、51%、15%和 13%。与 Leibovich 预后评分的外部验证(使用常规病理发现)相比,一致性指数为 0.792(p<0.05)。决策曲线分析也倾向于该新型模型的预测能力。
与 Leibovich 预后评分相比,加入血管侵犯将我们验证数据的预测准确性提高了 1.4%。评分 7 或更高的患者在 10 年内发生转移疾病的概率超过 85%。因此,他们可以被认为是辅助治疗试验的候选者。